Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate

Show simple item record

dc.contributor.author Kehinde, E.O.
dc.contributor.author Al-Maghrebi, M.
dc.contributor.author Sheikh, M.
dc.contributor.author Anim, J.T.
dc.date.accessioned 2013-06-25T19:01:36Z
dc.date.accessioned 2017-10-19T12:34:42Z
dc.date.available 2013-06-25T19:01:36Z
dc.date.available 2017-10-19T12:34:42Z
dc.date.issued 2013-03
dc.identifier.citation Kehinde, E. O., Al-Maghrebi, M., Sheikh, M., & Anim, J. T. (2013). Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. Journal of Urology, Link to full text: http://hinari-gw.who.int/whalecomwww.sciencedirect.com/whalecom0/science/article/pii/S0022534712049452 en_US
dc.identifier.issn 00225347
dc.identifier.uri http://197.255.68.203/handle/123456789/4121
dc.description.abstract Purpose: A steady increase in the incidence of septicemia after prostate biopsy in our unit between 2001 and 2005 prompted us to review our prophylactic antibiotic regimen. We compared the incidence of septicemia in patients undergoing prostate biopsy between 2001 and 2005 when only oral ciprofloxacin was used prophylactically (group 1) to the incidence among patients undergoing biopsy between 2006 and 2010 when a single dose of intravenous amikacin was added to ciprofloxacin (group 2). Materials and Methods: In group 1 the 300 patients were given 500 mg oral ciprofloxacin twice daily 1 day before and for 2 days after the biopsy while in group 2 the 897 patients, in addition to the ciprofloxacin previously mentioned, received 500 mg intravenous amikacin 30 minutes before the biopsy. Patients admitted to the hospital with septicemia after prostate biopsy had urine and blood culture and sensitivity tests. The number of patients in whom septicemia developed in each group after prostate biopsy and the microorganisms isolated from the urine and blood of such patients were compared using the chi-square test. Results: Septicemia was seen in 24 of 300 (8%) and 15 of 897 (1.7%) patients in groups 1 and 2, respectively (p <0.001). In group 1 the rate of septicemia after prostate biopsy was 2.1% and 13% in 2001 and 2005, respectively (p <0.001). In group 2 the rate of septicemia was 1.5% in 2006 and 1.6% in 2010 (p <0.25). Escherichia coli resistant to quinolones was responsible for 33 of 39 (84.6%) septicemic cases. Conclusions: The addition of amikacin to ciprofloxacin prophylaxis significantly reduces the incidence of septicemia after prostate biopsy. en_US
dc.language.iso en en_US
dc.publisher Journal of Urology en_US
dc.subject antibiotic prophylaxis en_US
dc.subject biopsy en_US
dc.subject ciprofloxacin en_US
dc.subject prostate en_US
dc.subject sepsis en_US
dc.title Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search UGSpace


Browse

My Account